Sai Parenterals Limited — PPTs, 26-05-2026: Investor Presentation

**Sai Parenterals: Q4 & FY26 Performance and Growth Strategy**

Sai Parenterals has posted strong results, with FY26 consolidated revenue at ₹381 Cr. Standalone performance was impressive, with revenue, EBITDA, and PAT growing 31%, 23%, and 64% YoY, respectively, driven by robust CDMO momentum. CDMO revenue saw a remarkable surge of over 250% YoY.

The company is strategically expanding its global footprint, particularly in injectables, and capitalizing on the CDMO opportunity. The upcoming manufacturing facility in Adelaide, Australia, is set to strengthen its presence in regulated markets. Key growth drivers include new product development and expanding the branded generic formulations business internationally.

The acquisition of Noumed Pharmaceuticals has significantly enhanced the CDMO platform, providing access to regulated markets like Australia and New Zealand and strengthening revenue visibility through long-term supply agreements. The company is investing in R&D, with a new center planned to support product development and regulatory filings.

Looking ahead, Sai Parenterals is focused on expanding its global injectable formulations market, leveraging its manufacturing and R&D capabilities for the CDMO segment, and growing its branded generics business in international markets.